Latest Cardiology News

CONNEQT Health delivered sharp FY26 revenue growth and reduced its statutory loss as Pulse sales and clinical subscriptions expanded. But the ASX-listed medtech group ended the year with negative net assets, heavy cash burn and a material uncertainty over its ability to continue as a going concern.

Enlitic has secured a US$806,000 contract to migrate 10.6 million medical imaging studies for University of Michigan Health-Sparrow. The project also gives its Ensight platform a first active integration with Sectra’s enterprise imaging environment.

Echo IQ says it sees a path to US FDA clearance for EchoSolv HF after receiving a Not Substantially Equivalent determination. The company is weighing an appeal, an Ombudsman review or a fresh 510(k) submission, but has not selected a route or set a firm timetable.

CONNEQT Health has inked a marketing deal with US longevity platform Blueprint to boost consumer sales of its FDA-cleared Pulse arterial health monitor, targeting health-conscious Americans focused on preventative care.

Pro Medicus' US arm, Visage Imaging, has landed a substantial 7-year, A$25 million contract to deploy its Visage 7 cloud-based imaging platform across Valley Health's hospital network in Virginia and West Virginia.

Pro Medicus delivered a robust FY26 with 28% underlying revenue growth, a surge in new contract wins worth $407 million, and a 25% increase in fully franked dividends, underpinned by strong AI product development and rapid implementations.

Imricor Medical Systems has ignited its US commercial operations with rapid adoption by top pediatric hospitals, buoyed by FDA pediatric clearances and clinical trial progress.

Philips has officially declared compatibility for Imricor’s interventional MR devices with its magnetic resonance systems, enabling commercial clinical use and collaboration at a leading cardiology congress.

ImpediMed reported a 3% revenue increase to $3.6 million in Q4 FY26, bolstered by a $15.3 million capital raise and strategic leadership hires as it pushes growth in cancer survivorship, heart health, and weight management.

Nyrada has dosed the first patient in its Phase IIa trial of Xolatryp targeting heart attack recovery, while strengthening its cash reserves and receiving a US patent allowance for its lead drug.

Imricor Medical Systems has officially launched its US commercial operations, securing Rady Children’s Hospital–San Diego as the first customer for its NorthStar iMR mapping system, following key FDA clearances including pediatric approvals.

EBR Systems has launched the WiSE Coupler in the US, a new accessory designed to improve the implantation of its wireless cardiac pacing electrode. The device has FDA clearance and was piloted in 10 procedures, marking another step in the company’s US commercial expansion.